Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...
In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...
Defendant Yisel Lopez has been found in contempt for violating an asset freeze order through the sale of property.
Armed with readouts from the PURPOSE 1 and 2 trials, Gilead Sciences is now gearing up for global regulatory submissions for ...
Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...
J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating on September 13. Chris Schott has ...
Genesis Therapeutics’ shiny AI drug discovery platform GEMS is catching on, having now caught the eye of Gilead Sciences. | ...
Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...